NO20073372L - GLP-1-analoge fusjonsproteinformuleringer - Google Patents
GLP-1-analoge fusjonsproteinformuleringerInfo
- Publication number
- NO20073372L NO20073372L NO20073372A NO20073372A NO20073372L NO 20073372 L NO20073372 L NO 20073372L NO 20073372 A NO20073372 A NO 20073372A NO 20073372 A NO20073372 A NO 20073372A NO 20073372 L NO20073372 L NO 20073372L
- Authority
- NO
- Norway
- Prior art keywords
- glp
- fusion protein
- fusion
- formulations
- protein formulations
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 4
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 title 1
- 108020001507 fusion proteins Proteins 0.000 title 1
- 102000037865 fusion proteins Human genes 0.000 title 1
- 230000004927 fusion Effects 0.000 abstract 3
- 230000002401 inhibitory effect Effects 0.000 abstract 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 230000037406 food intake Effects 0.000 abstract 1
- 235000012631 food intake Nutrition 0.000 abstract 1
- 230000002496 gastric effect Effects 0.000 abstract 1
- 230000030135 gastric motility Effects 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 230000000968 intestinal effect Effects 0.000 abstract 1
- 230000008991 intestinal motility Effects 0.000 abstract 1
- 208000002551 irritable bowel syndrome Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Sammendrag Oppfinnelsen angår en stabil løsningsformulering omfattende en GLP-1-Fc-fusjon med en pH mellom ca pH 6 og ca pH 8,5, analoger fusjonert med spesifikke lgG4-Fc-derivater. Disse formuleringene frembringer uventede og betydelig bedre kjemisk stabilitet sammenlignet med GLP-1-Fc-fusjoner ved en pH utenfor disse områder. Formuleringene inneholdende en GLP-1-Fc-fusjon er nyttig ved behandling av diabetes, fedme, irritabel tannsyndrom og andre tilstander som vil ha fordel av redusert plasmaglukose, inhibisjon av mage og/eller tarmmotilitet og inhibering av mage og/eller tanntømming, eller inhibering av matinntak.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64169004P | 2004-12-22 | 2004-12-22 | |
| PCT/US2005/045376 WO2006068910A1 (en) | 2004-12-22 | 2005-12-15 | Glp-1 analog fusion protein formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20073372L true NO20073372L (no) | 2007-07-16 |
Family
ID=36123207
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20073372A NO20073372L (no) | 2004-12-22 | 2007-06-29 | GLP-1-analoge fusjonsproteinformuleringer |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20090232807A1 (no) |
| EP (2) | EP1831252B1 (no) |
| JP (1) | JP2008525452A (no) |
| KR (1) | KR100879662B1 (no) |
| CN (1) | CN101044162B (no) |
| AT (1) | ATE435235T1 (no) |
| AU (1) | AU2005319432A1 (no) |
| BR (1) | BRPI0519393A2 (no) |
| CA (1) | CA2589647A1 (no) |
| CY (1) | CY1109269T1 (no) |
| DE (1) | DE602005015257D1 (no) |
| DK (1) | DK1831252T3 (no) |
| EA (1) | EA011166B1 (no) |
| ES (1) | ES2326906T3 (no) |
| IL (1) | IL183285A0 (no) |
| MX (1) | MX2007007565A (no) |
| NO (1) | NO20073372L (no) |
| PL (1) | PL1831252T3 (no) |
| PT (1) | PT1831252E (no) |
| SI (1) | SI1831252T1 (no) |
| UA (1) | UA87009C2 (no) |
| WO (1) | WO2006068910A1 (no) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100888022B1 (ko) * | 2006-12-21 | 2009-03-09 | 재단법인 목암생명공학연구소 | 면역글로불린 Ｆｃ와 인간 아포리포단백질（ａ）크링글절편의 융합단백질 ＬＫ8Ｆｃ |
| JP2008169195A (ja) * | 2007-01-05 | 2008-07-24 | Hanmi Pharmaceutical Co Ltd | キャリア物質を用いたインスリン分泌ペプチド薬物結合体 |
| ATE499088T1 (de) * | 2007-07-10 | 2011-03-15 | Lilly Co Eli | Glp-1-fc fusionsprotein-formulierung |
| EP2031064A1 (de) * | 2007-08-29 | 2009-03-04 | Boehringer Ingelheim Pharma GmbH & Co. KG | Verfahren zur Steigerung von Proteintitern |
| EP2435061A4 (en) | 2009-05-28 | 2013-03-27 | Amylin Pharmaceuticals Inc | DAMPING GLP-1 RECEPTOR AGONIST COMPOUNDS |
| EP2496249B1 (en) | 2009-11-03 | 2016-03-09 | Amylin Pharmaceuticals, LLC | Glp-1 receptor agonist for use in treating obstructive sleep apnea |
| JP5819946B2 (ja) * | 2010-05-17 | 2015-11-24 | ベータ ファーマシューティカルズ カンパニー リミテッド | 新規のグルカゴン様ペプチド類似体、組成物、および使用方法 |
| CN102533655A (zh) * | 2010-12-21 | 2012-07-04 | 青岛黄海制药有限责任公司 | 高效表达人源重组蛋白GLP1/Fc的CHO-S细胞株及其建立方法 |
| US9161953B2 (en) | 2010-12-22 | 2015-10-20 | Amylin Pharmaceuticals, Llc | GLP-1 receptor agonists for islet cell transplantation |
| KR20130049671A (ko) | 2011-11-04 | 2013-05-14 | 한미사이언스 주식회사 | 생리활성 폴리펩타이드 결합체 제조 방법 |
| US10441665B2 (en) | 2012-07-25 | 2019-10-15 | Hanmi Pharm. Co., Ltd. | Liquid formulation of long acting insulinotropic peptide conjugate |
| AR094821A1 (es) | 2012-07-25 | 2015-09-02 | Hanmi Pharm Ind Co Ltd | Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada |
| UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| AU2013366692B2 (en) | 2012-12-21 | 2017-11-23 | Sanofi | Dual GLP1/GIP or trigonal GLP1/GIP/Glucagon agonists |
| CN104173275A (zh) * | 2013-05-21 | 2014-12-03 | 深圳翰宇药业股份有限公司 | 度拉鲁肽注射剂及其制备方法 |
| CN104371019B (zh) | 2013-08-13 | 2019-09-10 | 鸿运华宁（杭州）生物医药有限公司 | 一种能与glp-1r特异性结合的抗体及其与glp-1的融合蛋白质 |
| EP3080154B1 (en) | 2013-12-13 | 2018-02-07 | Sanofi | Dual glp-1/gip receptor agonists |
| EP3080152A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Non-acylated exendin-4 peptide analogues |
| WO2015086728A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
| WO2015086733A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/glucagon receptor agonists |
| MX387560B (es) * | 2014-03-31 | 2025-03-18 | Hanmi Pharmaceutical Co Ltd | Procedimiento para mejorar la solubilidad de proteínas y péptidos usando un enlace del fragmento fc de inmunoglobulina. |
| TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑 |
| TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物 |
| TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑 |
| US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
| CN104327187B (zh) * | 2014-10-11 | 2018-06-08 | 上海兴迪金生物技术有限公司 | 一种重组人GLP-1-Fc融合蛋白 |
| WO2016077806A1 (en) * | 2014-11-13 | 2016-05-19 | AskGene Pharma, Inc. | Fusion proteins with dual receptor agonist activities |
| PT3257524T (pt) * | 2015-02-11 | 2020-11-27 | Gmax Biopharm Llc | Preparação de solução estabilizada de proteína de fusão de anticorpo glp-1r farmacêutica |
| US10993993B2 (en) * | 2015-05-28 | 2021-05-04 | Immunoforge Co., Ltd. | Pharmaceutical composition for treating muscle atrophy or sarcopenia including glucagon-like peptide (GLP-1) or GLP-1 receptor agonist |
| AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
| TW201706291A (zh) | 2015-07-10 | 2017-02-16 | 賽諾菲公司 | 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物 |
| UA127495C2 (uk) | 2015-12-23 | 2023-09-13 | Амджен Інк. | Виділений антигензв'язуючий білок, який специфічно зв'язується з поліпептидом рецептора шлункового інгібіторного пептиду (gipr) людини, та фармацевтична композиція, яка його містить |
| GB201621987D0 (en) * | 2016-12-22 | 2017-02-08 | Archer Virgil L See Archer Sheri A Arecor Ltd | Novel composition |
| IL313587A (en) | 2017-01-17 | 2024-08-01 | Amgen Inc | Method of treating or ameliorating metabolic disorders using glp-1 receptor agonists conjugated to antagonists for gastric inhibitory peptide receptor (gipr) |
| EA201992502A1 (ru) | 2017-06-20 | 2020-04-22 | Эмджен Инк. | Способ лечения или уменьшения интенсивности метаболических нарушений с применением белков, связывающих рецептор гастроингибиторного пептида (gipr), в комбинации с агонистами glp-1 |
| EP3642238A1 (en) | 2017-06-21 | 2020-04-29 | Amgen Inc. | Method of treating or ameliorating metabolic disorders using antagonistic binding proteins for gastric inhibitory peptide receptor (gipr)/glp-1 receptor agonist fusion proteins |
| US12297272B2 (en) | 2017-08-15 | 2025-05-13 | Eianco US inc. | IgG Fc variants for veterinary use |
| KR102589234B1 (ko) | 2017-11-21 | 2023-10-16 | 일라이 릴리 앤드 캄파니 | 둘라글루티드를 함유하는 조성물 및 사용 방법 |
| TWI829687B (zh) | 2018-05-07 | 2024-01-21 | 丹麥商諾佛 儂迪克股份有限公司 | 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物 |
| TWI705820B (zh) | 2018-06-22 | 2020-10-01 | 美商美國禮來大藥廠 | Gip/glp1促效劑組合物 |
| WO2020190591A1 (en) | 2019-03-15 | 2020-09-24 | Eli Lilly And Company | Preserved formulations |
| CA3177693A1 (en) | 2019-04-05 | 2020-10-05 | Eli Lilly And Company | Therapeutic uses of dulaglutide |
| US20210187077A1 (en) * | 2019-12-23 | 2021-06-24 | Idaho State University | GLP-1 Agonist Conjugates for Sustained Glycemic Control |
| JP2025504612A (ja) * | 2021-12-31 | 2025-02-13 | サンシャイン・レイク・ファーマ・カンパニー・リミテッド | Ｇｌｐ－１及びｇｄｆ１５の融合タンパク質並びにその使用 |
| TWI880227B (zh) * | 2022-05-30 | 2025-04-11 | 丹麥商西蘭製藥公司 | 澱粉素類似物之液體調配物 |
| WO2026021575A1 (zh) * | 2024-07-26 | 2026-01-29 | 鸿运华宁（杭州）生物医药有限公司 | 一种gipr抗体融合蛋白质的药用稳定溶液制剂及其应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5118666A (en) * | 1986-05-05 | 1992-06-02 | The General Hospital Corporation | Insulinotropic hormone |
| HUT76369A (en) * | 1994-07-29 | 1997-08-28 | Smithkline Beecham Corp | Novel soluble protein compounds |
| GB9511935D0 (en) * | 1995-06-13 | 1995-08-09 | Smithkline Beecham Plc | Novel compound |
| US6376653B1 (en) * | 1998-09-28 | 2002-04-23 | Smithkline Beecham Plc | Tie2 antagonist antibodies |
| IL155812A0 (en) * | 2000-12-07 | 2003-12-23 | Lilly Co Eli | Glp-1 fusion proteins |
| WO2002079415A2 (en) * | 2001-03-30 | 2002-10-10 | Lexigen Pharmaceuticals Corp. | Reducing the immunogenicity of fusion proteins |
| US20030191056A1 (en) * | 2002-04-04 | 2003-10-09 | Kenneth Walker | Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins |
| DK1641823T3 (da) * | 2003-06-12 | 2011-12-12 | Lilly Co Eli | GLP-1-analog fusionsproteiner |
-
2005
- 2005-12-15 DK DK05854150T patent/DK1831252T3/da active
- 2005-12-15 EP EP05854150A patent/EP1831252B1/en not_active Expired - Lifetime
- 2005-12-15 CN CN2005800355972A patent/CN101044162B/zh not_active Ceased
- 2005-12-15 CA CA002589647A patent/CA2589647A1/en not_active Abandoned
- 2005-12-15 PT PT05854150T patent/PT1831252E/pt unknown
- 2005-12-15 MX MX2007007565A patent/MX2007007565A/es active IP Right Grant
- 2005-12-15 AU AU2005319432A patent/AU2005319432A1/en not_active Abandoned
- 2005-12-15 AT AT05854150T patent/ATE435235T1/de active
- 2005-12-15 BR BRPI0519393-1A patent/BRPI0519393A2/pt active Search and Examination
- 2005-12-15 PL PL05854150T patent/PL1831252T3/pl unknown
- 2005-12-15 US US11/720,939 patent/US20090232807A1/en not_active Abandoned
- 2005-12-15 WO PCT/US2005/045376 patent/WO2006068910A1/en not_active Ceased
- 2005-12-15 SI SI200530779T patent/SI1831252T1/sl unknown
- 2005-12-15 DE DE602005015257T patent/DE602005015257D1/de not_active Expired - Lifetime
- 2005-12-15 JP JP2007548310A patent/JP2008525452A/ja not_active Withdrawn
- 2005-12-15 EA EA200701364A patent/EA011166B1/ru not_active IP Right Cessation
- 2005-12-15 KR KR1020077014068A patent/KR100879662B1/ko not_active Expired - Lifetime
- 2005-12-15 EP EP09160182A patent/EP2168982A1/en not_active Withdrawn
- 2005-12-15 UA UAA200706803A patent/UA87009C2/ru unknown
- 2005-12-15 ES ES05854150T patent/ES2326906T3/es not_active Expired - Lifetime
-
2007
- 2007-05-17 IL IL183285A patent/IL183285A0/en unknown
- 2007-06-29 NO NO20073372A patent/NO20073372L/no not_active Application Discontinuation
-
2009
- 2009-08-06 CY CY20091100832T patent/CY1109269T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2589647A1 (en) | 2006-06-29 |
| HK1107570A1 (en) | 2008-04-11 |
| IL183285A0 (en) | 2007-09-20 |
| JP2008525452A (ja) | 2008-07-17 |
| EA200701364A1 (ru) | 2007-10-26 |
| DK1831252T3 (da) | 2009-10-05 |
| PT1831252E (pt) | 2009-09-17 |
| EA011166B1 (ru) | 2009-02-27 |
| ES2326906T3 (es) | 2009-10-21 |
| EP2168982A1 (en) | 2010-03-31 |
| KR20070089187A (ko) | 2007-08-30 |
| KR100879662B1 (ko) | 2009-01-20 |
| CY1109269T1 (el) | 2014-07-02 |
| WO2006068910A1 (en) | 2006-06-29 |
| DE602005015257D1 (no) | 2009-08-13 |
| US20090232807A1 (en) | 2009-09-17 |
| CN101044162B (zh) | 2010-10-27 |
| EP1831252B1 (en) | 2009-07-01 |
| CN101044162A (zh) | 2007-09-26 |
| EP1831252A1 (en) | 2007-09-12 |
| BRPI0519393A2 (pt) | 2009-01-20 |
| UA87009C2 (ru) | 2009-06-10 |
| PL1831252T3 (pl) | 2009-11-30 |
| MX2007007565A (es) | 2007-07-24 |
| SI1831252T1 (sl) | 2009-12-31 |
| AU2005319432A1 (en) | 2006-06-29 |
| ATE435235T1 (de) | 2009-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20073372L (no) | GLP-1-analoge fusjonsproteinformuleringer | |
| TW200507870A (en) | GLP-1 analog fusion proteins | |
| NO20076415L (no) | GLP-1 pegylerte forbindelser | |
| UA92451C2 (en) | Polyethelene glycol link glp-1 compounds | |
| NZ515902A (en) | Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, and type 2 diabetes | |
| WO2005011592A3 (en) | Substituted indazole-o-glucosides | |
| WO2005012243A3 (en) | Substituted indole-o-glucosides | |
| NO20091734L (no) | Glucagonreseptorantagonistforbindelser, preparater inneholdende slike forbindelser, og metoder for anvendelse | |
| WO2005012318A3 (en) | Substituted fused heterocyclic c-glycosides | |
| UA87991C2 (en) | Substituted indole-o-glucosides | |
| PL1751184T3 (pl) | Białka fuzyjne FGF-21 | |
| WO2006042152A3 (en) | Vasoactive intestinal polypeptide pharmaceuticals | |
| WO2002044113A3 (en) | Use of(-) (3-halomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia | |
| WO2007044591A3 (en) | Vasoactive intestinal polypeptide pharmaceuticals | |
| DE50210906D1 (de) | Arzneimittel enthaltend deuterium zur behandlung der zuckerkrankheit | |
| WO2003024946A3 (en) | Oxamate derivatives containing a variously substituted nitrogen heterocycle | |
| NO20030021D0 (no) | Heterosykliske forbindelser som er inhibitorer for enzymet DPP-IV | |
| RU2005106768A (ru) | Способ лечения хронических гонартринов у больных остеоартрозом |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |